,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'trastuzumab', 'astrazeneca']
when i joind astrazeneca, a destiny breast study with trastuzumab-deruxtecan was the first study handed to me. watching the reaction of the oncology community to destiny breast 04 data at #asco22 is just humbling! a great day in the fight against breast cancer. very proud
Cancer Scientist | In May 22 I quit my job at BigPharma to build @itsYendou and accelerate the race to cancer cure. Here I tweet about my journey